Financial Overview - Climb Bio reported cash, cash equivalents, and marketable securities of $187.4 million as of June 30, 2025, expected to fund operations through 2027[11]. - Climb Bio's net loss for Q2 2025 was $8.7 million, compared to a net loss of $54.9 million in Q2 2024[19]. - The total operating expenses for Q2 2025 were $10.7 million, significantly lower than the $56.4 million reported for Q2 2024, which included a one-time IPR&D expense of $51.7 million[19]. Research and Development - Research and Development (R&D) expenses for Q2 2025 were $6.6 million, a significant increase from $1.0 million in Q2 2024[11]. - The company achieved the first patient in (FPI) for the Phase 1b/2a trials of budoprutug in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), with enrollment ongoing[4]. - The Phase 2 trial for primary membranous nephropathy (pMN) is on track to initiate in the coming weeks[4]. - Climb Bio plans to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for CLYM116 in IgA nephropathy (IgAN) in the second half of 2025[6]. - The company anticipates initial results from the Phase 1 trial of the subcutaneous formulation of budoprutug in healthy volunteers in the first half of 2026[5]. Administrative Changes - General and Administrative (G&A) expenses for Q2 2025 were $4.1 million, compared to $3.7 million in the same period of 2024[11]. - Climb Bio appointed Edgar D. Charles, M.D., MSc as Chief Medical Officer in June 2025, bringing over 20 years of experience in immunology-focused pharmaceutical development[7].
Eliem Therapeutics(ELYM) - 2025 Q2 - Quarterly Results